Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.39 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.39 |
| ▸ | CCR1 | P32246 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29832653 | 1.00 | MAPT (0.54) | MAPTALDH1A1KDM4EMEN1USP2 | |
| SCHEMBL1773094 | 0.84 | PRMT5 (0.53) | MAPTALDH1A1KDM4EMEN1USP2 | |
| SCHEMBL10022978 | 0.80 | MAPT (0.44) | MAPTALDH1A1KDM4EMEN1USP2 | |
| SCHEMBL9124792 | 0.78 | MAPT (0.36) | MAPTALDH1A1KDM4EMEN1USP2 | |
| SCHEMBL21591589 | 0.77 | PARP1 (0.35) | MAPTALDH1A1KDM4EMEN1USP2 | |
| SCHEMBL29463681 | 0.76 | MAPT (0.50) | MAPTALDH1A1KDM4EMEN1USP2 | |
| SCHEMBL87693 | 0.76 | MAPT (0.50) | MAPTALDH1A1KDM4EMEN1USP2 | |
| SCHEMBL30335572 | 0.76 | MAPT (0.50) | MAPTALDH1A1KDM4EMEN1USP2 | |
| Quinoline SCHEMBL28253161 | 0.76 | ALDH1A1 (0.63) | MAPTALDH1A1KDM4EPOLBPRMT5 | |
| SCHEMBL3069598 | 0.75 | KDM4E (0.58) | MAPTALDH1A1KDM4EMEN1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 964 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260068882-A1 | ARTHROPOD CONTROLLING COMPOSITION | FIRMENICH & CIE (CH) | 2026-03-12 | — | — | US | claimed |
| CN-113905612-B | Arthropod control composition | 弗门尼舍有限公司 | 2025-04-08 | — | — | CN | claimed |
| CN-116268351-B | Hazelnut-flavor essence base material and preparation method and application thereof | 湖南嘉利香料有限公司 | 2025-02-18 | — | — | CN | claimed |
| CN-116268351-A | Hazelnut-flavor essence base material and preparation method and application thereof | 湖南嘉利香料有限公司 | 2023-06-23 | — | — | CN | claimed |
| CN-114805225-B | Hydrogenation method of methyl quinoxaline | 苏州中车氢能动力技术有限公司 | 2022-09-23 | — | — | CN | claimed |
| CN-114805225-A | Hydrogenation method of methyl quinoxaline | 苏州中车氢能动力技术有限公司 | 2022-07-29 | — | — | CN | claimed |
| US-11365370-B2 | Fragrance compositions | THE PROCTER & GAMBLE COMPANY (US) | 2022-06-21 | — | — | US | claimed |
| US-20220142158-A1 | ARTHROPOD CONTROL COMPOSITIONS | FIRMENICH SA (CH) | 2022-05-12 | — | — | US | claimed |
| US-20220142157-A1 | ARTHROPOD CONTROLLING COMPOSITION | FIRMENICH SA (CH) | 2022-05-12 | — | — | US | claimed |
| CN-113905612-A | Arthropod control composition | 弗门尼舍有限公司 | 2022-01-07 | — | — | CN | claimed |
| EP-2091929-A1 | AGENTS THAT DISRUPT CELLULAR REPLICATION AND THEIR USE IN INHIBITING PATHOLOGICAL CONDITIONS | The European Molecular Biology Laboratory (DE) | 2009-08-26 | — | — | EP | claimed |
| EP-1758905-B1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINE, THE PRODUCTION THEREOF AND THE USE IN THE FORM OF A DDP-IV INHIBITOR | BOEHRINGER INGELHEIM INT (DE) | 2009-04-29 | — | — | EP | claimed |
| CN-101421257-A | Agents that disrupt cellular replication and their use in inhibiting pathological conditions | EUROPEAN MOLECULAR BIOLOGY LAB EMBL (DE) | 2009-04-29 | — | — | CN | claimed |
| WO-2009024542-A2 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-26 | — | — | WO | claimed |
| EP-1515681-B1 | NON-CRYSTALLINE PERFUME OR FLAVOUR DELIVERY SYSTEM | FIRMENICH & CIE (CH) | 2008-09-24 | — | — | EP | claimed |
| WO-2007107352-A1 | AGENTS THAT DISRUPT CELLULAR REPLICATION AND THEIR USE IN INHIBITING PATHOLOGICAL CONDITIONS | THE EUROPEAN MOLECULAR BIOLOGY LABORATORY (DE) | 2007-09-27 | — | — | WO | claimed |
| US-5939568-A | Accelerated catalysis of olefinic epoxidations | THE SCRIPPS RESEARCH INSTITUTE (US) | 1999-08-17 | — | — | US | claimed |
| WO-1998033786-A9 | ACCELERATED CATALYSIS OF OLEFINIC EPOXIDATIONS | — | 1998-12-30 | — | — | WO | claimed |
| WO-1998033786-A1 | ACCELERATED CATALYSIS OF OLEFINIC EPOXIDATIONS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1998-08-06 | — | — | WO | claimed |
| US-4925901-A | STORAGE STAABILITY, ONIUM ION CATALYST | THE DOW CHEMICAL COMPANY (US) | 1990-05-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260068882-A1 | ARTHROPOD CONTROLLING COMPOSITION | CNOT9, MSL1, MT-CO2 | MAPT 4191/4885ALDH1A1 3224/4885KDM4E 1705/4885 |
| US-20220142157-A1 | ARTHROPOD CONTROLLING COMPOSITION | AGO2, NOP2, FBL | MAPT 2538/4885ALDH1A1 3272/4885KDM4E 1606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.